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a b s t r a c t 
Background: The objective of this study was to explore the clinical and microbiological outcomes asso- 
ciated with substituting inhaled aztreonam lysine for an intravenous antibiotic in the treatment of acute 
pulmonary exacerbations of CF. 
Methods: An open-label randomised crossover pilot trial was conducted at a UK CF centre among 16 
adults with CF and P. aeruginosa infection. Median [IQR] age was 29.5 [24.5-32.5], mean ± SD forced ex- 
piratory volume in 1 second (FEV1) was 52.4 ± 14.7 % predicted. Over the course of two exacerbations, 
participants were randomised to sequentially receive 14 days of inhaled aztreonam lysine plus IV colis- 
timethate (AZLI + IV), or dual IV antibiotics (IV + IV). Primary outcome was absolute change in % predicted 
FEV1. Other outcomes evaluated changes in quality of life, bacterial load and the lung microbiota. 
Results: The difference between mean change in lung function at day 14 between AZLI + IV and IV + IV 
was + 4.6% (95% CI 2.1-7.2, p = 0.002). The minimum clinically important difference of the Cystic Fibrosis 
Revised Questionnaire (CFQ-R) was achieved more frequently with AZLI + IV (10/12, 83.3%) than IV + IV 
(7/16, 43.8%), p = 0.05. No differences were observed for modulation of serum white cell count, C-reactive 
protein or sputum bacterial load. Microbiome compositional changes were observed with IV + IV (Bray- 
Curtis r 2 = 0.14, p = 0.02), but not AZLI + IV (r 2 = 0.03, p = 0.64). 
Conclusion: In adults with CF and P. aeruginosa infection experiencing an acute pulmonary exacerbation, 
AZLI + IV improved lung function and quality of life compared to the current standard treatment. These 
findings support the need for larger definitive trials of inhaled antibiotics in the acute setting. 
Clinical trial registration: EudraCT 2016-002832-34 
ClinicalTrials.org NCT02894684 
© 2020 The Author(s). Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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. Introduction 
Acute pulmonary exacerbations occur frequently in people with 
ystic fibrosis (pwCF) and are associated with significant morbid- ∗ Corresponding author at: Adult CF Unit, Liverpool Heart & Chest Hospital NHS 
oundation Trust, Liverpool, UK, L14 3PE. 
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Fibrosis, https://doi.org/10.1016/j.jcf.2020.12.012 ty, loss of lung function, poorer quality of life and decreased sur- 
ival [1–3] . Overall, there is limited data to support treatment de- 
isions in acute exacerbations but UK guidelines recommend treat- 
ent with 10-14 days of dual intravenous (IV) antibiotics [4] . How- 
ver, such extended courses increase treatment burden, cause sys- 
emic side-effects and their effect on the lung microbiome is in- 
ompletely understood. New treatment options are indicated and 
he James Lind Alliance partnership identified the treatment of 
cute pulmonary exacerbations as a top 10 research priority area 
f shared importance for patient and clinical communities [5] . Fibrosis Society. This is an open access article under the CC BY-NC-ND license 
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Inhaled antibiotics are used frequently in CF to target chronic 
. aeruginosa infection. Colistimethate, tobramycin, levofloxacin and 
ztreonam lysine preparations have proven clinical benefits in the 
hronic suppression of P. aeruginosa and are licensed and recom- 
ended for use in the UK [6] . Little is known regarding the util-
ty of inhaled antibiotics in the acute setting, but possible bene- 
ts may include direct targeting of the end organ (lung) with high 
putum concentrations and minimal systemic exposure. Aztreonam 
ysine for inhalation (AZLI) has demonstrated superiority over neb- 
lised tobramycin in a chronic suppressive role, yet in 2017 was 
tilised in just a quarter of those with chronic P. aeruginosa in the 
K. [ 7 , 8 ] Given its known clinical benefits and safety record in the
hronic infection setting, in addition to its potential availability as 
 new therapeutic option to a large proportion of the UK CF popu- 
ation, this study aimed to explore the clinical and microbiological 
ffects of substituting AZLI for an IV anti-pseudomonal agent in the 
reatment of acute pulmonary exacerbations of CF. 
. Methods 
The Aztreonam lysine for inhalation for the treatment of acute 
xacerbations of cystic fibrosis study (AZTEC-CF, ClinicalTrials.org 
CT02894684) was a pilot open-label randomised cross-over study 
onducted at an adult CF centre in the United Kingdom (Liverpool 
eart & Chest Hospital NHS Foundation Trust, referred to herein 
s LHCH). Adult pwCF were eligible for recruitment if they had 
hronic P. aeruginosa lung infection (defined here as the Leeds cri- 
eria with at least one positive sample in the previous 6 months) 
nd forced expiratory volume in 1 second (FEV1) between 25% and 
5% predicted at the time of enrolment, which was in an outpa- 
ient clinic prior to admission for intravenous antibiotics [9] . Exclu- 
ion criteria included previous Burkholderia spp. growth and prior 
se of AZLI. Ethical and regulatory approval was granted by the 
orth-West Research Ethics Committee and Health Research Au- 
hority (16/NW/0741). 
. Randomisation and interventions 
Recruited pwCF were randomised to receive two treatment reg- 
mens sequentially over the course of their next two exacerba- 
ions requiring intravenous antibiotics. The threshold for treat- 
ent inclusion was standardised using the modified Fuch’s cri- 
eria, which included the need for intravenous antibiotic treat- 
ent and a recent change of least two of the following crite- 
ia: change in sputum volume/colour, increased cough, increased 
atigue, malaise/lethargy, anorexia/weight loss [10] . Unstratified, 
lock randomisation in groups of four was carried out prospec- 
ively using Statsdirect® (Statsdirect Ltd, 2013) and kept in sealed 
nvelopes to be referred to by the investigators at the time of par- 
icipants’ first exacerbation. Treatment regimens were “AZLI + IV”
14 days of AZLI 75mg tds plus IV colistimethate 2 Mega Units tds) 
nd “IV + IV” (14 days of IV colistimethate 2 Mega Units tds plus 
 second IV antipseudomonal antibiotic selected by the admitting 
hysician). AZLI + IV rather than dual inhaled antimicrobials were 
hosen given concerns the inhaled route alone may not treat any 
otential systemic component of an acute pulmonary exacerbation. 
olistimethate was selected over tobramycin for a number of rea- 
ons. Firstly, UK guidelines recommend colistimethate as useful in 
he setting of resistant P. aeruginosa. The prevalence of the multi- 
rug resistant, transmissible Liverpool Epidemic Strain (LES) of P. 
eruginosa is high at LHCH and overall colistimethate resistance 
emains low in this population [11] . Secondly, UK guidelines rec- 
mmend a standardised dosing regimen for colistimethate of 1-2 
U TDS in adults with CF [4] , thus negating the need for extra 
enepuncture and dose adjustments as compared to tobramycin. 
t was felt by the study team that, given the small nature of the 2 rial, any potential under dosing and subsequent requirement for 
rolonged courses would introduce further risk of bias into study 
nd colistimethate was felt to offer a more appropriate option. All 
ntibiotics were administered at dosages and frequencies recom- 
ended by national guidelines [4] . Study participation was cen- 
ored at 24 months. 
. Procedures 
Participants received each inpatient intervention alongside stan- 
ard care including chest physiotherapy, nebulised bronchodilators 
nd mucolytics (see Supplementary File 2, Figures E1-2). Chronic 
nhaled anti-pseudomonal therapy was stopped during both ex- 
cerbations. Spirometry and venepuncture were carried out and 
pontaneously expectorated sputum samples were collected on day 
 (pre) and day 14 (post) of treatment, with additional venepunc- 
ure and spirometry at day 7. A revised Cystic Fibrosis Question- 
aire (CFQ-R) was completed on day 1 and day 14. Expectorated 
putum samples were immediately refrigerated at 4 °C, before flash 
reezing in liquid nitrogen and storage in -80 °C freezers within 
4 h. Spirometry was performed by an accredited respiratory phys- 
ologist according to American Thoracic Society/European Respi- 
atory Society guidelines with predicted values calculated from 
lobal Lung Initiative reference ranges [ 12 , 13 ]. Blood samples were 
rocessed as per routine clinical samples in the local accredited 
HS laboratory. At day 14, participants were either discharged 
ome if deemed medically fit by the admitting team, or remained 
n inpatient to receive further intravenous antibiotics of the admit- 
ing team’s choosing. Day 14 decisions were recorded and the need 
or further antibiotics reported as an adverse event. 
. Outcomes 
The primary outcome was the absolute change in FEV1% pre- 
icted at day 14. Secondary outcomes included quality of life 
achievement of minimum clinically important difference (MCID) 
n the CFQ-R Respiratory Domain), sputum bacterial load, serum 
nflammatory markers, time to next pulmonary exacerbation, and 
afety [14] . Pre-specified exploratory analyses of changes in the 
tructure and composition of the sputum microbiome were also 
erformed. 
. Microbiological analyses 
Processing of sputum samples, quantitative culture, DNA extrac- 
ion, amplifications, library preparations and downstream analyses 
re presented in detail in Supplementary file 1. Briefly, DNA extrac- 
ion was performed using the ZymoBIOMICS TM DNA Miniprep Kit 
ZymoBIOMICS, USA) using the manufacturer’s protocol including 
ead-beating for cell lysis. Sequencing of the V4 hypervariable re- 
ion of the 16S rRNA gene was performed on the Illumina MiSeq 
latform according to the Schloss protocol with negative and posi- 
ive controls [15] . QIIME2 pipeline was used to align sequence vari- 
nts to the Greengenes 16S rRNA database version 13.5. A “core”
icrobiome was identified as previously described [ 16 , 17 ]. Taxa are 
resented as amplicon sequence variants (ASV) with resolution to 
enus or species level denoted by “g_” and “s_” respectively. The 
otal abundance of each taxa in each sample was computed by 
ultiplying its relative abundance within that sample by the to- 
al bacterial load determined by 16S rRNA gene qPCR. 
. Statistical analysis 
Statistical analyses were conducted in RStudio (v1.0.136, R Stu- 
io Inc). Continuous data are presented as mean ± SD or median 
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Table 1 
Clinical characteristics of participants in the AZTEC-CF study, with comparison by allocated sequence (n = 8 for both). 
Data presented as n (%), median [IQR] or mean ± SD. 
AZLI + IV/IV + IV IV + IV/AZLI + IV All 
Demographics 
Age 28.9 [25.4, 30.3] 29.7 [22.4, 33.1] 29.5 [24.5, 32.5] 
Sex, male 7 (87.5) 8 (100) 15 (93.8) 
Phe508del homozygous 8 (100) 3 (7.5) 11 (68.8) 
Phe508del heterozygous 0 (0.0) 5 (62.5) 5 (31.2) 
FEV1, % predicted 47.9 ± 14.4 56.9 ± 14.5 52.4 ± 14.7 
BMI, kg/m 2 22.6 [21.2, 25.0] 20.0 [19.1, 22.3] 22.1 [19.2, 23.6] 
Annualised IV days 26.0 [20.0, 35.3] 20.50 [6.8, 45.8] 26.0 [13.8, 45.8] 
Pancreatic insufficiency 6 (75.0) 8 (100.0) 14 (87.5) 
GORD 5 (62.5) 6 (75.0) 11 (68.8) 
CFRD 6 (75.0) 5 (62.5) 11 (68.8) 
Microbiology 
P. aeruginosa 8 (100.0) 8 (100.0) 16 (100.0) 
Liverpool Epidemic Strain 5 (62.5) 5 (62.5) 10 (62.5) 
S. aureus 4 (50.0) 0 (0.0) 4 (25.0) 
NTM 
M. avium complex 0 (0.0) 1 (12.5) 1 (6.2) 
M. abscessus complex 1 (12.5) 2 (25.0) 3 (18.8) 
Aspergillus spp. 2 (25.0) 1 (12.5) 3 (18.8) 
Medications 
Macrolide 8 (100.0) 7 (87.5) 15 (93.8) 
Proton pump inhibitor 8 (100.0) 4 (57.1) 12 (80.0) 
Ursodeoxycholic acid 6 (75.0) 4 (50.0) 10 (62.5) 
Dornase Alfa 6 (75.0) 6 (75.0) 12 (75.0) 
Nebulised antibiotic therapies 
Colistimethate 6 (75.0) 4 (50.0) 10 (62.5) 
Tobramycin 1 (12.5) 0 (0.0) 1 (12.5) 
Both 0 (0.0) 4 (50.0) 4 (25.0) 
Abbreviations: FEV1 = Forced expiratory volume in 1 second; BMI = Body Mass Index; GORD = Gastro-oesophageal 
reflux disease; CFRD = Cystic fibrosis related diabetes; NTM = Non-tuberculous mycobacteria 
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IQR] throughout. Baseline characteristics are tabulated and com- 
ared by treatment sequence in Table 1 . Subjects were included in 
n intention to treat analysis if they were randomised to a treat- 
ent sequence and received at least one administration of each 
reatment. 12 subjects initiated both treatments and were there- 
ore included for outcome analysis. For treatment effect estimation, 
ifferences between day 1 and day 14 were calculated were treated 
s paired data with treatments compared using Wilcoxon signed 
ank test or paired t-test depending on normality. This method was 
elt to be appropriate given that, by definition, benefit derived from 
 previous treatment has dissipated at the time of next exacerba- 
ion and is therefore unlikely to be prone to bias from carryover 
ffect. Times to next exacerbation were compared between treat- 
ents in a Kaplan-Meier analysis. Sensitivity analyses were per- 
ormed to assess the impact of dropouts by imputing best-case and 
orst-case scenarios. Given, the primary outcome was reported as 
bsolute change in % predicted FEV1, sensitivity analyses of the 
rimary outcome expressed in volume change and relative change 
ere performed. To assess changes in the lung microbiota, alpha 
nd beta-diversity measures were compared in paired samples be- 
ore and after treatment. For changes in alpha diversity (the vari- 
tion within a sample), we measured sample richness, Shannon 
nd Fisher’s diversity metrics. Assessment of statistical significance 
ere made using a Wilcoxon or Kruskal-Wallis test. To test the im- 
act of treatments on beta-diversity (variation between samples) 
e calculated Bray-Curtis dissimilarity indices, visualized variation 
n community structure using principle coordinate analysis (PCA) 
lots and performed pairwise permutational multivariate analysis 
f variance (PERMANOVA). For all between-treatment comparisons, 
nly those subjects with valid sputum samples for day 1 and 14 
f each treatment (n = 10, 40 samples in total) were included 
or analysis. Given the pilot nature of the clinical trial, analyses 
hould be considered exploratory, but whenpresented, unadjusted 
- values are presented throughout and a significance level of < 0.05 
as considered significant. t
3 . Results 
.1. Study participants 
Between January 2017 and January 2019, nineteen adult pwCF 
ere consented and sixteen randomised, see Fig. 1 . 28/32 (87.5%) 
xacerbations were completed within the study period. Two par- 
icipants withdrew consent prior to second exacerbation and two 
id not exacerbate a second time within the study timeframe, thus 
2 participants completed the study and were included for the pri- 
ary outcome analysis, see Fig. 1 . Median time between the two 
reatment periods was 118 days for those treated with IV + IV first 
nd 154 days in those treated with AZLI + IV first. Baseline demo- 
raphics and clinical characteristics are presented in Table 1 , at ex- 
cerbation baseline measures were similar between treatment pe- 
iod and sequence allocation groups. Equally, at the time of exac- 
rbation, on an individual level, deterioration in lung function, in- 
ammatory profiles and symptoms were generally similar across 
oth exacerbations, see Supplementary Table E1. 
For IV + IV, the second IV antibiotic used was meropenem 
g tds for 9 participants, ceftazidime 3g tds for 6 and 
iperacillin/tazobactam 4.5g tds for 1. Other treatment including 
ucolytics, corticosteroids and systemic bronchodilators was simi- 
ar between groups (see Supplementary Table E2). 
.2. Primary outcome 
At 14 days of treatment, AZLI + IV was associated with 
ignificantly greater lung function improvement than IV + IV 
 + 13.5% ± 11.0 versus 8.8% ± 10.1 respectively, mean [95% CI] 
reatment difference + 4.6% [2.1 to 7.2], p = 0.002), see Fig 2 A. Treat-
ent differences occurred in the second week, since improve- 
ents at day 7 were similar (mean differences + 0.6% [-6.1 to 7.4], 
 = 0.83), see Fig 2 B-C. An exploratory sensitivity analysis confirmed 
he primary outcome was robust regardless of baseline lung func- 
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Fig. 1. CONSORT Diagram for AZTEC-CF Study. 
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ion, volume of lung function improvement and relative lung func- 
ion improvement (Supplementary Figure E3). The imputation of 
issing data from drop-outs using worst-case/best case imputation 
avoured a treatment effect for AZLI + IV over IV + IV, see Supple-
entary Table E3. 
.3. Secondary outcomes 
AZLI + IV and IV + IV were both associated with improved CFQ- 
 Respiratory domain scores at day 14 ( + 13.9 [ + 2.8 to + 25.0]
nd + 11.1 [ + 0.5 to + 19.4] respectively). The minimum clinically 
mportant difference (MCID) was achieved more frequently with 
ZLI + IV, 10/12 (83.3%), as compared to 7/16 (43.8%) in the IV + IV
rm (Fisher’s exact test p = 0.04). 
Markers of systemic inflammation (serum white cell count 
nd C-reactive protein) were elevated in 18/28 (64.2%) and 
6/28 (57.1%) exacerbations respectively. There were no between- 
reatment differences for changes in white cell count or C-reactive 
rotein at day 14, see Table 2 . Similarly, no difference was seen for
ime to next exacerbation, Supplementary Figure E4, or changes in 
putum bacterial load, Table 2 . 
.4. Safety 
Treatment-emergent adverse events were reported during the 
tudy in 10/16 (62.5%) participants. Adverse events occurred at 
imilar frequencies for each treatment, see Table 3 . The most com- 
on adverse event was the requirement for more than 14 days of 4 ntibiotics and occurred equally for each treatment. Exaggerated 
ough was reported in the AZLI + IV arm only but did not result in
iscontinuation. 
.5. Treatment effects on the lung microbiota 
As expected, the lung microbiome of study participants was 
enerally dominated by Pseudomonas , see Fig. 3 . Analysis of se- 
uenced positive and negative controls confirmed results were not 
onfounded by major cross-contamination or sequence bias, see 
upplementary Figure S3. Alpha diversity was preserved across the 
ntire study period suggesting the CF microbiota community struc- 
ure is resilient to perturbation at the time of exacerbation, Sup- 
lementary Figure S5. This was also true when each treatment was 
onsidered separately, Supplementary Figure S5. 
To assess for compositional changes, pairwise permutational 
nalysis of variance was used to test the impact of treatment on 
eta-diversity. At day 1 i.e. pre-treatment, samples were compo- 
itionally similar (Bray-Curtis r 2 = 0.08, p = 0.24, see Fig. 4 A). How-
ver, after 14 days there were significant differences between treat- 
ents (Bray-Curtis r 2 = 0.18, p = 0.001), see Fig. 4 B. These differences
ppeared to be driven by changes in the IV + IV group. For exam- 
le, when comparing beta-diversity at day 1 and day 14 for each 
reatment, no change was seen for the AZLI + IV treatment (Bray- 
urtis r 2 = 0.03, p = 0.64), but was observed for the IV + IV treatment
Bray-Curtis r 2 = 0.14, p = 0.02). At the individual taxa level, a treat- 
ent effect for IV + IV, but not AZLI + IV, was seen against Prevotella
elaninogenica and Veillonella dispar , see Supplementary Figure S6. 
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Fig. 2. Paired between-treatment comparison of absolute change % predicted FEV1 at day 14 (A). Change of lung function over 14 days for AZLI + IV (B) and IV + IV (C). Data 
are presented as a paired boxplot with each participant represented by a smaller dot. 95% confidence interval (whiskers), mean (large dot) are also illustrated. For (B) and 
(C) data are presented as mean and 95% confidence interval. ∗∗p = 0.002 
Table 2 
Secondary outcomes. Data are presented as median [IQR]. Treatment effect were estimated by a paired Wilcoxon test and are presented at 
median [95% confidence interval]. 
AZLI + IV IV + IV 
Day 1 Day 14 Day 1 Day 14 Treatment effect p 
Blood 
n 12 12 16 16 12 
White cell 
count 
10 9 /ml 
12.3 
[11.3, 13.0] 
12.8 
[9.2, 16.1] 
11.8 
[7.55,14.50] 
11.7 
[7.9, 14.6] 
+ 0.4 
[-3.1, 4.5] 
0.73 
C-reactive 
protein mg/L 
7.0 
[ < 5.0, 22.3] 
4.0 
[4.0, 5.8] 
7.0 
[4.0, 40.5] 
4.0 
[4.0, 4.0] 
+ 4.0 
[-9 to 26] 
0.40 
Quantitative sputum culture 
n 11 11 13 13 11 
Total Bacteria 
Log10 CFU/ml 
5.8 
[5.4 to 7.3] 
5.9 
[5.3 to 7.4] 
6.6 
[6.3 to 7.0] 
6.4 
[5.7 to 7.0] 
+ 0.16 
[-1.0 to 1.4] 
0.76 
Total P. 
aeruginosa 
Log10 CFU/ml 
3.4 
[3.1 to 4.7] 
3.3 
[1.8 to 4.3] 
4.9 
[3.3 to 5.5] 
5.0 
[3.2 to 5.6] 
-1.03 
[-2.3 to 2.6]" 
0.11 
Sputum qPCR 
n 12 12 16 16 12 
Total 16S 
copies 
Log10 copies/ml 
8.1 
[7.5 to 8.6] 
7.9 
[7.2 to 8.0] 
8.1 
[7.9 to 8.6] 
8.2 
[7.5 to 8.5] 
+ 0.29 
[-0.5 to 1.1] 
0.44 
Table 3 
Treatment emergent adverse events reported during the AZTEC-CF study. 
AZLI + IV (n = 12) % IV + IV (n = 16) % p 
Total patients reporting an adverse event 6 50.0% 8 50.0% 0.70 
Adverse event 
> 14 days antibiotic therapy required 3 25.0% 4 25.0% > 0.99 
Drop in lung function 1 8.3% 0 0.0% 0.23 
Pyrexia 2 16.7% 1 6.3% 0.38 
Raised inflammatory markers 1 8.3% 2 12.5% 0.72 
Headache 0 0.0% 2 12.5% 0.20 
Cough 2 16.7% 0 0.0% 0.10 
Nausea 0 0.0% 1 6.3% 0.38 
Bloating 1 8.3% 0 0.0% 0.23 
Musculoskeletal pain 0 0.0% 1 6.3% 0.38 
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Fig. 3. Relative abundance of core taxa before and after each treatment. Each bar represents a sputum sample for each participant with Study ID denoted above the respective 
bar. Samples from exacerbations treated with IV + IV are in the top row and AZLI + IV in the bottom row. On the x-axis Day 1 or Day 14 is denoted. The relative abundance of 
all core taxa in each sample are represented by the proportion their respective colour occupies within the bar. 
Fig. 4. Principle co-ordinates analysis plots based upon an unweighted Bray-Curtis dissimilarity matrix shows no difference between samples pre-treatment on day 1 (A). 
After treatment on day 14 (B), samples clustered distinctly based upon the treatment received. Ellipses within the PCA plots represent 95% confidence around the geometric 
mean of samples. Samples are labelled with study ID. At day 14, improvements in quality of life (CFQ-R Respiratory Domain) was associated with reduced total abundance 
of Pseudomonas within the lung microbiome (C) and also cultured P. aeruginosa load (D). 
6 
F. Frost, G.R. Young, L. Wright et al. Journal of Cystic Fibrosis xxx (xxxx) xxx 
ARTICLE IN PRESS 
JID: JCF [m5G; December 21, 2020;9:24 ] 
N  
e
8
b
g
l
l
f
d
i  
c
9
o
c
a
M
t
i
t
a
r
m
f
t
a
t
o
i
i
e
F
w
i
t
w
C
p
e
w
e
b
a
s
g
t
t
c
f
3
c
s
[
t
t
s
t
t
a
s
p
B
o
a
b
o
I
g
C
c
d
i
p
p
o
P
a
l
t
w
t
t
i
p
C
a
fi
b
e
s
L
u
a
p
e
m
a
t
r
f
l
i
t
s
w
b
c
e
n
t
t
m
e
p
o
n
c
i
r
a
either IV + IV, nor AZLI + IV was associated with any overall differ-
nces in Pseudomonas . 
.6. Relationship between lung microbiota and clinical outcomes 
To explore whether changes in constituents of the lung micro- 
iome were associated with different clinical outcomes we investi- 
ated the relationship between the lung microbiota and changes in 
ung function, quality of life and time to next exacerbation. No re- 
ationship was found between changes lung microbiota and lung 
unction, or time to next exacerbation. Reductions in the abun- 
ance of Pseudomonas were associated with improvements in qual- 
ty of life at day 14 (r 2 = 0.37), a pattern that was also seen for
ultured pseudomonal load (r 2 = 0.18), see Fig. 4 C & 4 D. 
. Discussion 
This is the first study of the use of AZLI for the treatment 
f acute pulmonary exacerbations of CF and we found that the 
ombination of AZLI and intravenous colistimethate was associ- 
ted with significant improvement in lung function after 14 days. 
oreover, the cross-over design allowed a paired analysis to show 
hat the improvements for the AZLI + IV treatment arm were signif- 
cantly greater than those seen for standard dual intravenous an- 
ibiotic therapy. Both treatments were well tolerated with similar 
dverse event frequency between groups. In addition to the supe- 
ior lung function improvements seen in the AZLI treatment arm, 
ore subjects achieved the MCID for CFQ-R Respiratory domain 
ollowing the AZLI treatment arm than after standard intravenous 
herapy. 
The superior improvement seen here for AZLI + IV, equated to 
n extra 4.6% predicted FEV1 compared to the current standard 
reatment of two IV antibiotics and was robust across a number 
f sensitivity analysis. The IV + IV group saw limited lung function 
mprovement in the second week in keeping with previous stud- 
es of CF exacerbations, where average time to peak FEV1 in exac- 
rbations treated with IVs is approximately 8-9 days [18] . A poor 
EV1 response during treatment for an exacerbation is associated 
ith failure to recover pre-exacerbation lung function and occurs 
n approximately 25% of exacerbations [3] . In that regard, the con- 
inued improvements observed in the second week of treatment 
ith AZLI + IV may be of particular clinical significance. 
Inhaling antibiotics for acute infection is not a new idea in 
F: clinical trials were conducted as early as the 1980s where IV 
reparations were simply administered via a nebuliser [19] . How- 
ver, some constituents of intravenous antibiotics are associated 
ith lung irritation when given via the inhaled route, and those 
arly results were, perhaps unsurprisingly, mixed [ 19 , 20 ]. To the 
est of our knowledge only one other prospective clinical trial of 
n antibiotic optimised for inhalation (tobramycin) in the acute 
etting has been reported [21] . That work, also carried out by our 
roup, was focused on reducing renal toxicity but also found that 
he inhaled variant held superior clinical benefits in terms of time 
o next exacerbation compared to the IV preparation. 
Preparations optimised for inhalation can achieve sputum con- 
entrations much greater than their intravenous equivalents. AZLI, 
or example, achieves sputum maximal concentrations (Cmax) of 
83 μg/ml 10 mins post administration with a serum maximal con- 
entration of 0.4 μg/ml, whereas intravenous aztreonam achieves 
putum Cmax of 5.2 μg/ml and serum Cmax of ~100 μg/ml 
22] . Repeated courses of intravenous antibiotics result in ex- 
remely high systemic exposures with subsequent increased “off- 
arget” complications and reactions [23] . The high-pulmonary/low- 
ystemic exposure characteristics of AZLI therefore make it an at- 
ractive potential agent in the treatment of pulmonary exacerba- 
ions. The recent increase in available inhaled antibiotics should 7 llow further investigation of the inhalation route as a treatment 
trategy in CF pulmonary exacerbations. 
This is the first controlled clinical trial to explore the im- 
act of an inhaled antibiotic on the lung microbiota of pwCF. 
y limiting inter-individual variation as a confounder, the cross- 
ver design allowed us to more robustly assess treatment effects 
nd show IV + IV was associated with alterations in the micro- 
ial community composition not seen for AZLI + IV. At the level 
f individual taxa, the most striking difference was an effect of 
V + IV, but not AZLI + IV, against the anaerobes Prevotella melanino- 
enica and Veillonella dispar . Although not traditionally considered 
F pathogens, these species have been consistently identified in 
ulture-independent studies of the CF lung microbiome [24–26] . 
Our finding that neither cultured bacterial load nor total Pseu- 
omonas abundance was reduced in either treatment arm is 
nteresting since both arms included aggressive doses of anti- 
seudomonal antibiotics, an approach that is considered standard 
ractice in this setting. This finding is at odds with some previ- 
us microbiome studies reporting either increases or decreases in 
seudomonas relative abundance in response to treatment of an 
cute pulmonary exacerbation [ 24 , 27 ]. These studies generally re- 
ied solely on relative abundance and hence it is difficult to in- 
erpret a true effect. In keeping with results seen here, studies 
hich have more rigorously quantified P. aeruginosa before and af- 
er treatment for an acute exacerbation have reported no consis- 
ent effect [ 28 , 29 ]. Although no consistent effect against P. aerug- 
nosa was seen for either treatment, we found symptomatic im- 
rovements were associated with reductions in pseudomonal load. 
orrelation coefficients were not strong, suggesting other factors 
lso contribute to changes in quality of life, but importantly this 
nding was consistent across independent molecular and culture- 
ased analyses and supports previous observational work on the 
ffect of AZLI on the CF microbiome [30] . 
This study has limitations to consider. Primarily it is a small 
tudy at a single centre and generalisability is therefore uncertain. 
arger studies are warranted to confirm these findings and eval- 
ate if inhaled antibiotics can be used acutely, repeatedly and at 
 larger scale. Generalisability may also be limited in that most 
articipants in this study were male. The reasons for this are not 
ntirely clear but one explanation may lie in the protocol require- 
ent for at least 14 days inpatient treatment and women with CF 
re more likely to choose to be treated with home intravenous an- 
ibiotics [31] . Equally, subjects were only included if they had not 
eceived AZLI before and we cannot rule out a “honeymoon” ef- 
ect contributing to the difference between treatments. Neverthe- 
ess, regardless of superiority over intravenous antibiotics, the pos- 
tive results here, taken together with an earlier study of inhaled 
obramycin, suggest inhaled antibiotics may have role in the acute 
etting and further work is needed. [21] Once randomised, subjects 
ere not blinded to treatment and there exists an intrinsic risk of 
ias in that regard. A common limitation of cross-over studies is 
arryover effect, however in the setting of acute pulmonary exac- 
rbations any treatment effect is, by definition, lost at the time of 
ext exacerbation and we therefore believe risk of carryover bias 
o be low. The crossover design employed here improved the sta- 
istical efficiency of the study and allowed robust analysis of treat- 
ent effect for both clinical and microbiological outcomes. How- 
ver, there was a 12.5% dropout rate between the two treatment 
eriods and although sensitivity analyses confirmed the primary 
utcome analysis was robust in the face of drop-outs, this will be 
eed to be considered and accounted for in future studies 
A major strength of this study lies in its relevance to the CF 
ommunity, indeed AZTEC-CF is the only currently registered clin- 
cal trial which meets the recently identified James Lind Alliance 
esearch priorities relating to acute exacerbation (Priority 8) and 
ntibiotic related adverse events (Priority 9) [ 5 , 32 ]. 
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In summary, we found AZLI was associated with positive clin- 
cal outcomes when utilised in the management of acute pul- 
onary exacerbations of CF in adults infected with P. aeruginosa . 
hese findings inform and support the need for larger trials of AZLI 
n the acute setting. 
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